Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Chronic hepatitis C infection, diagnosed by positive anti-HCV antibodies and detected HCV RNA at screening~2. HCV infection of sub-GT1b confirmed by genotypic testing at screening.~3. HCV viral load =1,000 IU/mL at randomisation.~4. Patients who have never been previously treated with any other HCV treatment regimen.~Exclusion criteria:~1. HCV infection of mixed GT (1/2, 1/3, and 1/4) diagnosed by genotypic testing at screening.~2. HCV infection of sub-GT1a, mixed GT1a/1b, or undefined GT1.~3. Liver disease due to causes other than chronic HCV infection.~4. HIV infection.~5. Hepatitis B virus infection based on presence of HBs-Ag.~6. Confirmed or suspected active malignancy or history of malignancy within the last 5 years prior to screening.~7. History of illicit drug abuse other than cannabis or chronic alcohol abuse within 12 months prior to randomisation.~8. Subject is not willing to comply with the precautionary measures to prevent photosensitivity (avoid excessive sun exposure and use sun block on a daily basis).~9. Decompensated liver disease, or history of decompensated liver disease.~10. Clinical evidence of unstable cardiovascular disease which may further decompensate due to anemia.~11. Red blood cell disorders.~12. Body weight \<40 kg or \>125 kg.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Randomised 24-week arm (Type: EXPERIMENTAL): BI 207127 in combination with FDV and RBV for 24 weeks (randomised)
- Randomised 16-week arm (Type: EXPERIMENTAL): BI 207127-placebo, FDV-placebo and RBV-placebo for 8 weeks followed by BI 207127 in combination with FDV and RBV for 16 weeks (randomised)
- Allocated 24-week arm (Type: EXPERIMENTAL): BI 207127 in combination with FDV and RBV for 24 weeks (allocated to patients with compensated cirrhosis)

Based on this trial design, predict the completion outcome and termination type (if applicable).